Literature DB >> 21771571

Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies.

Jakob R Passweg1, Mei-Jie Zhang, Vanderson Rocha, Fangyu Kan, Richard E Champlin, Luis M Isola, Adrian P Gee, John Gibson, Mary J Laughlin, Hillard M Lazarus, Alison Loren, David I Marks, Alois Gratwohl, Mary Eapen.   

Abstract

We examined the effect of donor characteristics on graft failure (<5% donor chimerism within 3 months after transplantation), acute and chronic graft-versus-host disease (aGVHD, cGVHD), and survival after unrelated donor reduced-intensity conditioning (RIC) transplantation in 709 patients with hematologic malignancies. Donor-recipient pairs were HLA typed at HLA-A, -B, -C, and -DRB1 (allele-level). A total of 501 patients were >95% donor chimerism, 145 patients were 5% to 95%, and 63 patients were <5%. The only donor characteristic associated with transplantation outcome was donor-recipient HLA matching. One- or 2-loci mismatched transplants led to higher grade 2-4 (relative risk [RR] = 1.27, P = .035) and grade 3-4 (RR = 1.85, P < .001) aGVHD and 2-loci mismatched transplants higher mortality (RR = 2.22, P < .001). Graft failure was higher after transplantation of bone marrow (RR = 2.33, P = .002). Donor age, parity, and donor sex match were not associated with transplantation outcome. Donor-recipient HLA matching is the only donor characteristic predictive for survival after RIC regimens for hematologic malignancies.
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21771571      PMCID: PMC3217167          DOI: 10.1016/j.bbmt.2011.07.008

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  13 in total

Review 1.  Pathophysiology and treatment of graft-versus-host disease.

Authors:  M E Flowers; E Kansu; K M Sullivan
Journal:  Hematol Oncol Clin North Am       Date:  1999-10       Impact factor: 3.722

Review 2.  Hematopoietic stem-cell transplantation.

Authors:  Edward A Copelan
Journal:  N Engl J Med       Date:  2006-04-27       Impact factor: 91.245

3.  Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe.

Authors:  P Ljungman; A Urbano-Ispizua; M Cavazzana-Calvo; T Demirer; G Dini; H Einsele; A Gratwohl; A Madrigal; D Niederwieser; J Passweg; V Rocha; R Saccardi; H Schouten; N Schmitz; G Socie; A Sureda; J Apperley
Journal:  Bone Marrow Transplant       Date:  2006-03       Impact factor: 5.483

Review 4.  Non-myeloablative transplants for malignant disease.

Authors:  R F Storb; R Champlin; S R Riddell; M Murata; S Bryant; E H Warren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2001

5.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Authors:  H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas
Journal:  Transplantation       Date:  1974-10       Impact factor: 4.939

6.  Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age.

Authors:  C Kollman; C W Howe; C Anasetti; J H Antin; S M Davies; A H Filipovich; J Hegland; N Kamani; N A Kernan; R King; V Ratanatharathorn; D Weisdorf; D L Confer
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

7.  Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Authors:  Robert J Soiffer; Jennifer Lerademacher; Vincent Ho; Fangyu Kan; Andrew Artz; Richard E Champlin; Steven Devine; Luis Isola; Hillard M Lazarus; David I Marks; David L Porter; Edmund K Waller; Mary M Horowitz; Mary Eapen
Journal:  Blood       Date:  2011-04-04       Impact factor: 22.113

8.  Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants.

Authors:  Sophia S B Randolph; Theodore A Gooley; Edus H Warren; Frederick R Appelbaum; Stanley R Riddell
Journal:  Blood       Date:  2003-09-11       Impact factor: 22.113

9.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

10.  Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.

Authors:  Reuven Or; Michael Y Shapira; Igor Resnick; Avraham Amar; Aliza Ackerstein; Simcha Samuel; Memet Aker; Elizabeth Naparstek; Arnon Nagler; Shimon Slavin
Journal:  Blood       Date:  2002-09-19       Impact factor: 22.113

View more
  12 in total

1.  GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT.

Authors:  R Parody; L Lopez-Corral; O L Godino; I G Cadenas; A P Martinez; L Vazquez; R Martino; C Martinez; C Solano; P Barba; D Valcarcel; T Caballero-Velazquez; F J Marquez-Malaver; J Sierra; D Caballero; J A Perez-Simón
Journal:  Bone Marrow Transplant       Date:  2014-10-13       Impact factor: 5.483

2.  Non-myeloablative conditioning for second hematopoietic cell transplantation for graft failure in patients with non-malignant disorders: a prospective study and review of the literature.

Authors:  K Mallhi; P J Orchard; W P Miller; Q Cao; J Tolar; T C Lund
Journal:  Bone Marrow Transplant       Date:  2017-01-16       Impact factor: 5.483

3.  Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure.

Authors:  Troy C Lund; Jessica Liegel; Nelli Bejanyan; Paul J Orchard; Qing Cao; Jakub Tolar; Claudio Brunstein; John E Wagner; Michael R Verneris; Daniel Weisdorf
Journal:  Am J Hematol       Date:  2015-10       Impact factor: 10.047

4.  Reduced-intensity conditioning regimen with low-dose ATG-F for unrelated bone marrow transplant is associated with lower non-relapse mortality than a regimen with low-dose TBI: a single-center retrospective analysis of 103 cases.

Authors:  Shigeo Fuji; Niina Ueno; Nobuhiro Hiramoto; Yoshitaka Asakura; Kimikazu Yakushijin; Yutaro Kamiyama; Saiko Kurosawa; Sung-Won Kim; Yuji Heike; Takuya Yamashita; Takahiro Fukuda
Journal:  Int J Hematol       Date:  2013-10-04       Impact factor: 2.490

5.  Subsequent donation requests among 2472 unrelated hematopoietic progenitor cell donors are associated with bone marrow harvest.

Authors:  Robert N Lown; Sameer Tulpule; Nigel H Russell; Charles F Craddock; Rochelle Roest; J Alejandro Madrigal; Bronwen E Shaw
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

Review 6.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.

Authors:  Jan J Cornelissen; Alois Gratwohl; Richard F Schlenk; Jorge Sierra; Martin Bornhäuser; Gunnar Juliusson; Zdenek Råcil; Jacob M Rowe; Nigel Russell; Mohamad Mohty; Bob Löwenberg; Gerard Socié; Dietger Niederwieser; Gert J Ossenkoppele
Journal:  Nat Rev Clin Oncol       Date:  2012-09-04       Impact factor: 66.675

7.  High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients.

Authors:  Zaid Al-Kadhimi; Zartash Gul; Wei Chen; Daryn Smith; Muneer Abidi; Abhinav Deol; Lois Ayash; Lawrence Lum; Edmund K Waller; Voravit Ratanatharathorn; Joseph Uberti
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-04       Impact factor: 5.742

8.  Impact of Human Leukocyte Antigen Loci and Haplotypes on Intestinal Acute Graft-versus-host Disease after Human Leukocyte Antigen-matched Sibling Peripheral Blood Stem Cell Transplantation.

Authors:  Fa-Hong Yan; Mei Wang; Jian-Feng Yao; Er-Lie Jiang; Ming-Zhe Han
Journal:  Chin Med J (Engl)       Date:  2017-06-05       Impact factor: 2.628

9.  The Relationship between STR-PCR Chimerism Analysis and Chronic GvHD Following Hematopoietic Stem Cell Transplantation.

Authors:  Seyed Asadollah Mousavi; Mina Javadimoghadam; Ardeshir Ghavamzadeh; Kamran Alimoghaddam; Azadeh Sayarifard; Seyed-Hamidollah Ghaffari; Bahram Chahardouli; Ali Basi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-01-01

10.  Donor characteristics and hematopoietic stem cell transplantation outcome: experience of a single center in Southern Brazil.

Authors:  Alessandra Paz; Lisandra Rigoni; Gustavo Fischer; Monise Schittler; Annelise Pezzi; Vanessa Valim; Alice Dahmer; Bruna Zambonato; Bruna Amorin; Filipe Sehn; Maria Aparecida da Silva; Liane Daudt; Lucia Silla
Journal:  Hematol Transfus Cell Ther       Date:  2018-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.